Assessing treatment response in patients with primary biliary cholangitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of ursodeoxycholic acid (UDCA) in newly diagnosed patients with primary biliary cholangitis (PBC) by measuring specific biomarkers, sCD163 and sMR, which may predict treatment response. The study will involve collecting blood samples, conducting Fibroscan assessments, administering questionnaires, and performing liver biopsies to gather comprehensive data on patient health and treatment outcomes. By understanding the relationship between these biomarkers and treatment efficacy, the study seeks to improve management strategies for PBC patients who may not respond adequately to UDCA.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Newly diagnosed with Primary biliary cholangitis
* No treatment with UDCA

Exclusion Criteria:

* Patient under 18 years
* Expected lifetime under 6 months
* Expected liver transplantation within 6 months
* Liver cancer
* Cirrhosis from other causes

Where it's running

• Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark
  Aarhus C, Central Jutland, Denmark Recruiting

Study contacts

• Study coordinator: Lars Bossen, PhD-student
• Email: larsbossen@clin.au.dk
• Phone: +4522800676

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Non-invasive blood and imaging tests for metabolic liver disease

  This project tests whether blood tests and imaging scans can diagnose and stage metabolic-associated steatohepatitis (MASH) and liver fibrosis in adults with metabolic risk factors.

  Recruiting at 4 sites Foundation for the National Institutes of Health · Miami, Florida and 3 other locations · NCT07122700

• Evaluating LivQ-box® for diagnosing liver inflammation

  This study is testing if the LivQ-box® can help doctors better diagnose liver inflammation in people with nonalcoholic fatty liver disease.

  Recruiting Wuxi Hisky Medical Technology Co Ltd · Beijing, Beijing Municipality · NCT06802731

• Ursodeoxycholic acid helps prevent glucose intolerance in statin users

  This study is testing if taking Ursodeoxycholic acid along with a common cholesterol medication can help people with high cholesterol avoid problems with blood sugar levels.

  Recruiting at 2 sites First Affiliated Hospital Xi'an Jiaotong University · Xi'an, Shaanxi and 1 other locations · NCT06684106

• Identifying liver disease-specific gut microbiomes

  This study is trying to find out if certain gut bacteria are linked to chronic liver diseases in adults, including autoimmune hepatitis and primary biliary cholangitis, by analyzing blood and stool samples from patients and their household members.

  Recruiting Chungnam National University Hospital · Daejeon, Jung-gu · NCT06519162

• Biobank for cholestatic liver diseases

  This study is collecting samples and health information from people with cholestatic liver diseases to see if it can help us better understand these conditions and improve how we detect and predict them.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT03445585

• Fenofibrate added to UDCA for people with primary biliary cirrhosis not fully responding to UDCA

  This trial tests adding fenofibrate to UDCA for adults with primary biliary cirrhosis who did not fully respond to UDCA alone.

  Recruiting Phase 3 Xijing Hospital of Digestive Diseases · Xi'an, Shaanxi · NCT02823366

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.